ABSTRACT
Sarcoidosis is a chronic multisystemic disease of unknown aetiology, characterised by non-caseating granulomas. Ocular involvement rate ranges from 30% to 60% among individuals with sarcoidosis, and can vary widely, making the diagnosis a challenge to the ophthalmologist. Cutaneous manifestations occur in about 22% of sarcoidosis cases, but eyelid involvement is rare. Eyelid swelling and nodules are the most frequent forms of eyelid involvement, but other findings have been reported. The joint analysis of clinical history, ancillary exams and compatible biopsy is needed for the diagnosis, as well as the exclusion of other possible conditions. This review aims to describe the different forms of presentations, the clinical reasoning and treatment options for ocular, eyelid and orbital sarcoidosis.
Subject(s)
Endophthalmitis , Eye Diseases , Ophthalmologists , Sarcoidosis , Endophthalmitis/complications , Eye Diseases/etiology , Eyelids/pathology , Granuloma/pathology , Humans , Sarcoidosis/complications , Sarcoidosis/diagnosisABSTRACT
BACKGROUND/AIMS: In patients with hemifacial spasm (HFS), treatment relieves eyelid spasms on the affected side, thus changes in corneal topography and eyelid morphometry may be observed after treatment. We aimed to evaluate these parameters during a 4-month period in patients with HFS treated with botulinum toxin A (BTX-A). METHODS: This prospective study evaluated eyelid morphometric and corneal topographic changes in patients with HFS before onabotulinum toxin A application, and after 15â days and 2, 3 and 4â months. RESULTS: 24 patients were treated with BTX-A. On the normal side, the mean palpebral fissure height (PF), interpalpebral surface area (ISA), steep K and astigmatism values were 8.7±1.98â mm, 122.09±39.37â mm2, 44.99±1.45â D and 0.9±0.64â D, respectively, before treatment. A statistically significant difference was not observed in these parameters after treatment (p>0.05). On the affected side, the mean PF, ISA, steep K and astigmatism were 5.5±1.77â mm, 67.68±28.49â mm2, 46.91±3.57â D and 2.63±2.46â D, respectively, before treatment. We observed a statistically significant (p<0.05) increase in the mean PF and ISA on the affected side 15â days (8.36±1.91â mm and 115.92±34.44â mm2, respectively), 2 months (8.18±1.80â mm and 112.22±33.57â mm2, respectively) and 3 months (7.27±1.65â mm and 95.48±27.80â mm2, respectively) after treatment. A statistically significant decrease in steep K and astigmatism was observed at 2 months (45.14±1.20â D and 1.01±0.58â D, respectively) and 3â months (45.64±1.77â D and 1.36±1.31â D, respectively) after treatment. CONCLUSIONS: The results suggest that treatment with BTX-A in patients with HFS leads to eyelid and corneal changes on the affected eye that are significant during the known period of action of the toxin. Thus, caution should be taken when performing ophthalmological examination in patients with HFS, since it may vary according to BTX-A period of action.
Subject(s)
Blepharospasm/etiology , Botulinum Toxins, Type A/therapeutic use , Cornea/pathology , Corneal Topography/methods , Eyelids/diagnostic imaging , Hemifacial Spasm/complications , Aged , Aged, 80 and over , Blepharospasm/diagnosis , Blepharospasm/drug therapy , Eyelids/physiopathology , Female , Follow-Up Studies , Hemifacial Spasm/diagnosis , Hemifacial Spasm/drug therapy , Humans , Male , Middle Aged , Neuromuscular Agents/therapeutic use , Prognosis , Prospective Studies , Time FactorsABSTRACT
PURPOSE: To evaluate blink rate effects by a novel light-emitting diode (LED) timer device (PISC) on non-dry eye (DE) subjects and DE patients during a reading task on liquid crystal display (LCD) screens, in different environmental conditions. METHODS: This was a case-control study that included 15 DE patients and 15 non-DE subjects as controls. Participants had their blink rates measured while they read an electronic format text. These tasks were performed in four different conditions: with and without a LED timer device in two visits, and with and without air conditioning. All participants completed the Ocular Surface Disease Index and were examined by best spectacle-corrected visual acuity exam, biomicroscopy, Schirmer test 1, fluorescein staining and break-up time and lissamine green staining (Oxford scale grading). RESULTS: Outcomes between reading tasks conditions were compared independently for each group and blink rate frequency was higher in tasks with LED timer device, with and without air conditioning, for the DE group (p<0.0001), and with air conditioning for the control group (p<0.05). CONCLUSIONS: An LED timer device increased blink frequency for DE and control groups. Further studies need to be carried out in order to evaluate long-term effects of this new device, as well as its assessment with different reading scenarios.